TransCode's lofty goal is delivering a cancer-free future for all cancer patients. Our core belief is that cancer can be overcome through the intelligent design and efficient delivery of targeted therapeutics. Our lead therapeutic candidate, TTX-MC138, targets microRNA-10b, or miRNA-10b, considered the master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and several others.
Our other preclinical programs include two solid tumor programs, TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1, or PD-L1, and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. TransCode also has three cancer agnostic programs, TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I, or RIG-I, targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells.
Until now, targeting biomarkers that are the primary drivers of cancer onset, progression and recurrence have been locked behind the challenge of delivery – cytosolic delivery to engage these known targets.
TransCode believes it has overcome this barrier, opening the door to a broad array of cancer therapies -- a disease with the highest unmet need that affects everyone. It is through the design and optimization of this technology that TransCode has devised an elegant solution -- TTX -- a proprietary delivery platform for the transport of targeted therapeutics to cancer cells. With their world class team and know how, TransCode has a rapidly expanding platform of drug candidates designed to target a variety of tumor indications with the goal of long-term treatment survival.
Company Details
- Employees
- 14
- Founded
- -
- Address
- 73b Chapel St, Newton,massachusetts 02458,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- transcodetherapeutics.com
- Keywords
- Oncology, RNA, Diagnostics, Nucleic Acid Therapeutics, Orphan Disease Designation, Metastasis, Checkpoint Inhibitor, Pattern Recognition Receptor, mRNA vaccine, CRISPR.
- HQ
- Newton, Massachusetts
Transcode Therapeutics, Inc. Questions
Transcode Therapeutics, Inc.'s website is transcodetherapeutics.com
Transcode Therapeutics, Inc.'s LinkedIn profile is https://www.linkedin.com/company/transcodetherapeutics
Transcode Therapeutics, Inc. has
14 employees.
View email and phone details for 14
employees at Transcode Therapeutics, Inc..
Transcode Therapeutics, Inc.'s industry is
Biotechnology Research
Transcode Therapeutics, Inc.'s top competitors are
Acrivon Therapeutics, Inc.,
Casebia Therapeutics,
Voyager Therapeutics, Inc.,
Kano Therapeutics,
Carmine Therapeutics,
Aldeyra Therapeutics,
Ksq Therapeutics, Inc.,
Prelude Therapeutics,
Verve Therapeutics,
Acer Therapeutics Inc..
Transcode Therapeutics, Inc.'s categories are Biotechnology Research
Transcode Therapeutics, Inc.'s founding year is 2016
